Following a full submission
rufinamide (Inovelon®) is not recommended for use within NHS Scotland as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients four years and older.
The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
The licence holder has indicated their decision to resubmit.
Download detailed advice107KB (PDF)
- Medicine name:
- rufinamide 100mg, 200mg and 400mg tablets (Inovelon)
- SMC ID:
- seizures associated with Lennox-Gastaut syndrome (LGS) as adjunctive therapy in patients four years and older
- Pharmaceutical company
- Eisai Ltd
- BNF chapter
- Central nervous system
- Submission type
- Not recommended
- Date advice published
- 12 November 2007